DeepMed Research

Abramson Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Employees: -

Market Cap: -

Website: http://www.pennmedicine.org

Clinical Trials

Early FDG PET in Melanoma

Not Applicable

Terminated

Conditions: Clinical Stage III Nodal or Intransit Disease or Resectable Stage IV Melanoma

Interventions: Radiation: FDG PET/CT imaging

First Posted Date: 2016-03-23

Last Posted Date: 2021-07-23

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT02716077

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

C-Acetate PET/CT Imaging to Evaluate Treatment Changes in Prostate Cancer

Early Phase 1

Completed

Conditions: Prostate Cancer Patients

Interventions: Drug: 11C-Acetate

First Posted Date: 2016-03-22

Last Posted Date: 2022-05-18

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 6

Registration Number: NCT02715583

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Indocyanine Green for Central Nervous System Tumors

Phase 1

Completed

Conditions: Suspected Central Nervous System Tumors

Interventions: Drug: Indocyanine Green (ICG)
Radiation: Intraoperative near-infrared (NIR)

First Posted Date: 2016-03-16

Last Posted Date: 2021-10-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 336

Registration Number: NCT02710240

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

PDT Plus Vitamin D3 for Anal Dysplasia

Phase 1

Withdrawn

Conditions: Anal Dysplasia
Carcinoma in Situ

Interventions: Drug: Gliolan
Drug: Vitamin D3 cholecalciferol)
Other: Photodynamic Therpay

First Posted Date: 2016-03-03

Last Posted Date: 2022-11-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Registration Number: NCT02698293

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Evaluating the Effect of Perioperative Caloric Restriction Program on Perioperative Outcomes in Patients With Obesity and Endometrial Cancer

Not Applicable

Terminated

Conditions: Endometrial Cancer
Obese

Interventions: Other: Perioperative Caloric Restriction Program

First Posted Date: 2016-01-28

Last Posted Date: 2020-03-10

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 8

Registration Number: NCT02665962

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Pembrolizumab in Patients Failing to Respond to or Relapsing After CAR T Cell Therapy for Relapsed or Refractory Lymphomas

Phase 1

Completed

Conditions: CD19+ Diffuse Large B-cell Lymphomas
Mantle Cell Lymphomas
Follicular Lymphomas

Interventions: Drug: Pembrolizumab

First Posted Date: 2016-01-08

Last Posted Date: 2021-07-22

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 12

Registration Number: NCT02650999

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Optional Sub-study to Intraoperative Imaging With ICG Registry

Completed

Conditions: Lung, Prostate, Breast, Colon, Pancreatic, Renal, Bladder,Thyroid, Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut) Cancer
Cancer of Neuro-onc, Parathyroid, Desmoid Tumors, Melanoma Cancer
Cancer of the Ovarian, Head and Neck,GI (Foregut - Esophagus),GI (Midgut), Sarcoma Cancer

First Posted Date: 2016-01-08

Last Posted Date: 2021-06-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 291

Registration Number: NCT02651246

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Intraoperative Imaging With ICG Registry

Completed

Conditions: Lung Nodule, Breast, Kidney,Parathyroid, Mediastinal, Skin Mass, Soft Tissue, Prostate, Stomach Pleural, Head and Neck, and Are at Risk of Recurrence

First Posted Date: 2015-12-28

Last Posted Date: 2021-06-24

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 291

Registration Number: NCT02640170

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1

Completed

Conditions: Metastatic
Melanoma
Non Small Cell Lung Cancer (NSCLC)
Pancreatic Cancer
Breast Cancer

Interventions: Radiation: Radiotherapy
Drug: MEDI4736
Drug: Tremelimumab

First Posted Date: 2015-12-24

Last Posted Date: 2025-03-25

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 53

Registration Number: NCT02639026

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

Phase 1

Recruiting

Conditions: Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Interventions: Drug: [18F]FluorThanatrace
Radiation: PET/CT imaging sessions

First Posted Date: 2015-12-22

Last Posted Date: 2024-08-27

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 35

Registration Number: NCT02637934

Locations: 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy